Drug Information

Drug (ID: DG01484) and It's Reported Resistant Information

• Name: Amrubicin
• Synonyms: Amrubicin; 110267-81-7; UNII-93N13LB4Z2; C25H25NO9; 93N13LB4Z2; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(((2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Amrubicin [USAN:INN]; amrubicina; amrubicine; amrubicinum; Amrubicin Api; (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl]oxy}-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Amrubicin (USAN/INN); Amrubicin(SM-5887); SCHEMBL9140; CHEMBL1186894; EX-A161; CHEBI:135779; HY-B0067; ZINC3780800; 3441AH; DB06263; LS41109; AC-31129; D08854; W-60403; Q4748723; W-200813; (1S,3S)-3-acetyl-3-amino-5,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2-deoxy-beta-D-erythro-pentopyranoside; 5,12-Naphthacenedione, 9-acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)-
• Indication:
  In total 1 Indication(s)
  Malaria [ICD-11: 1F45]; Phase 3; [1]
• Formula: 3
• IsoSMILES: CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N
• InChI: InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
• InChIKey: VJZITPJGSQKZMX-XDPRQOKASA-N
• PubChem CID: 3035016
• ChEBI ID: CHEBI:135779
• TTD Drug ID: D03DDR
• DrugBank ID: DB06263

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Quinone reductase 1 (NQO1) [1]

• Sensitive Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Molecule Alteration: Missense mutation; p.P187S (c.559C>T)
• Wild Type Structure: Method: X-ray diffraction; Resolution: 2.30 Å; PDB: 1QBG
• Mutant Type Structure: Method: X-ray diffraction; Resolution: 2.20 Å; PDB: 4CET

RMSD: 0.58; TM score: 0.99168; Amino acid change: P187S

• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: A549 cells; Lung; Homo sapiens (Human); CVCL_0023
• In Vitro Model: NCI-H69 cells; Lung; Homo sapiens (Human); CVCL_1579
• In Vitro Model: NCI-H460 cells; Lung; Homo sapiens (Human); CVCL_0459
• In Vitro Model: NCI-H23 cells; Lung; Homo sapiens (Human); CVCL_1547
• In Vitro Model: PC-1 cells; Pancreas; Homo sapiens (Human); CVCL_S978
• In Vitro Model: PC-10 cells; Lung; Homo sapiens (Human); CVCL_7088
• In Vitro Model: QG56 cells; Lung; Homo sapiens (Human); CVCL_6943
• In Vitro Model: RERF-LC-MT cells; Lung; Homo sapiens (Human); CVCL_A473
• In Vitro Model: Sk-LC-6 cells; Lung; Homo sapiens (Human); CVCL_5474
• In Vitro Model: PC9 cells; Lung; Homo sapiens (Human); CVCL_B260
• In Vitro Model: SK-LC-2 cells; Lung; Homo sapiens (Human); CVCL_5468
• In Vitro Model: SK-LC-17 cells; Lung; Homo sapiens (Human); CVCL_5466
• In Vitro Model: SK-LC-1 cells; Lung; Homo sapiens (Human); CVCL_5458
• In Vitro Model: SBC3 cells; Bone marrow; Homo sapiens (Human); CVCL_1678
• In Vitro Model: RERF-LC-OK cells; Central nervous system; Homo sapiens (Human); CVCL_3154
• In Vitro Model: RERF-LC-MS cells; Lung; Homo sapiens (Human); CVCL_1655
• In Vitro Model: PC6 cells; Adrenal gland; Rattus norvegicus (Rat); CVCL_7091
• In Vitro Model: NCI-H417 cells; Lung; Homo sapiens (Human); CVCL_1602
• In Vitro Model: NCI-H1688 cells; Liver; Homo sapiens (Human); CVCL_1487
• In Vitro Model: DMS53 cells; Lung; Homo sapiens (Human); CVCL_1177
• In Vitro Model: ACC-LC-94 cells; Lung; Homo sapiens (Human); CVCL_7032
• In Vitro Model: ACC-LC-80 cells; Lymph node; Homo sapiens (Human); CVCL_7028
• In Vitro Model: ACC-LC-73 cells; Lung; Homo sapiens (Human); CVCL_7026
• In Vitro Model: ACC-LC-67 cells; Lymph node; Homo sapiens (Human); CVCL_7024
• In Vitro Model: ACC-LC-5 cells; Cervical lymph node; Homo sapiens (Human); CVCL_7020
• In Vitro Model: ACC-LC-48 cells; Pericardial effusion; Homo sapiens (Human); CVCL_7018
• In Vitro Model: ACC-LC-314 cells; Lung; Homo sapiens (Human); CVCL_7011
• In Vitro Model: ACC-LC-174 cells; Lung; Homo sapiens (Human); CVCL_7007
• In Vitro Model: ACC-LC-172 cells; Pericardial effusion; Homo sapiens (Human); CVCL_7005
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: CellTiter 96 AQueous One assay
• Mechanism Description: The missense mutation p.P187S (c.559C>T) in gene NQO1 cause the sensitivity of Amrubicin by unusual activation of pro-survival pathway

References

• Ref 1: C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicinJ Thorac Oncol. 2011 Nov;6(11):1826-32. doi: 10.1097/JTO.0b013e318229137d.